Post by Unipharma SA

Unipharma is proud to announce a new strategic partnership with Cerbios Pharma. Unipharma and Cerbios have signed an exclusive distribution agreement for the launch of SF68 SLIPIDO®, an innovative solution designed to support cardio-metabolic health. Switzerland will become the first market worldwide where this new product will be introduced. Developed by Cerbios and based on the proprietary probiotic strain SF68, supported by more than 40 years of clinical evidence, SF68 SLIPIDO® reflects the growing scientific understanding of the relationship between intestinal microbiota, lipid metabolism, and metabolic protection. This partnership brings together: • Cerbios’ scientific and manufacturing excellence • Unipharma’s trusted distribution network Together, we aim to bring innovative, high-quality solutions to healthcare professionals and patients across Switzerland. “Launching SF68 SLIPIDO® in Switzerland reflects our commitment to a market that values scientific rigor and innovation,” said Monica Colombo, Head of Commercial Operations at Unipharma. SF68 SLIPIDO® will be available in Swiss pharmacies starting March, supported by professional education initiatives for healthcare professionals. We look forward to this exciting collaboration and to contributing to the future of preventive health and microbiome-based solutions. #LifeSciences #HealthcareInnovation #Pharma #Microbiome #Switzerland #UnipharmaSwitzerland #swissquality #since1947 #youourpriority #bridgingneeed #deliveringsolutions